Research programme: small molecule therapeutics - Syros Pharmaceuticals

Drug Profile

Research programme: small molecule therapeutics - Syros Pharmaceuticals

Alternative Names: CDK12/12 inhibitors - Syros Pharmaceuticals; Cyclin-dependent kinase 12/13 inhibitors - Syros Pharmaceuticals; SY 351; THZ1; THZ531

Latest Information Update: 06 Apr 2017

Price : $50

At a glance

  • Originator Syros Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Syros Pharmaceuticals; Whitehead Institute for Biomedical Research
  • Class Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; Gene expression modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Cancer; Ewing's sarcoma; Neuroblastoma; Ovarian cancer; Small cell lung cancer
  • Research Alzheimer's disease; Autoimmune disorders; Polycystic kidney disease

Most Recent Events

  • 15 May 2017 Syros pharmaceuticals plans to file an IND application with the USFDA in USA for Cancer
  • 03 Apr 2017 Pharmacodynamics data from a preclinical study in Cancer presented at the presented at 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 31 Mar 2017 Research programme: cancer therapeutics - Syros Pharmaceuticals is available for licensing as of 20 Mar 2017. www.syros.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top